Half-year report · Q2
2590.TEDINET S100WMQW
Period2025-01-21 → 2025-07-20
Filed2025-09-03
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥117.7bn | 2025-01-21 → 2025-07-20 | Cons. | Net sales |
| Revenue | ¥237.2bn | 2024-01-21 → 2025-01-20 | Cons. | Net sales (5-year summary) |
| Revenue | ¥117.6bn | 2024-01-21 → 2024-07-20 | Cons. | Net sales |
| Operating income | ¥1.4bn | 2025-01-21 → 2025-07-20 | Cons. | Operating income |
| Operating income | ¥2.3bn | 2024-01-21 → 2024-07-20 | Cons. | Operating income |
| Ordinary income | ¥69m | 2025-01-21 → 2025-07-20 | Cons. | Ordinary income |
| Ordinary income | ¥3.0bn | 2024-01-21 → 2025-01-20 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2024-01-21 → 2024-07-20 | Cons. | Ordinary income |
| Profit before tax | ¥69m | 2025-01-21 → 2025-07-20 | Cons. | Income before income taxes |
| Profit before tax | ¥6.5bn | 2024-01-21 → 2024-07-20 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.4bn | 2025-01-21 → 2025-07-20 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.8bn | 2024-01-21 → 2025-01-20 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.9bn | 2024-01-21 → 2024-07-20 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥1.9bn | 2025-01-21 → 2025-07-20 | Cons. | Profit loss |
| Net income | ¥4.7bn | 2024-01-21 → 2024-07-20 | Cons. | Profit loss |
| Total assets | ¥196.2bn | at 2025-07-20 | Cons. | Assets |
| Total assets | ¥185.2bn | at 2025-01-20 | Cons. | Assets |
| Total assets | ¥200.3bn | at 2024-07-20 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥105.5bn | at 2025-07-20 | Cons. | Liabilities |
| Total liabilities | ¥91.7bn | at 2025-01-20 | Cons. | Liabilities |
| Net assets / equity | ¥90.7bn | at 2025-07-20 | Cons. | Net assets |
| Net assets / equity | ¥93.5bn | at 2025-01-20 | Cons. | Net assets |
| Net assets / equity | ¥94.2bn | at 2024-07-20 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥28.0bn | at 2025-07-20 | Cons. | Cash and deposits |
| Cash and deposits | ¥30.7bn | at 2025-01-20 | Cons. | Cash and deposits |
| Cash & equivalents | ¥25.9bn | at 2025-07-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥29.6bn | at 2025-01-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥36.3bn | at 2024-07-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥33.7bn | at 2024-01-20v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.1bn | 2025-01-21 → 2025-07-20 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥10.8bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.5bn | 2024-01-21 → 2024-07-20 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥6.2bn | 2025-01-21 → 2025-07-20 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11.6bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.1bn | 2024-01-21 → 2024-07-20 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.6bn | 2025-01-21 → 2025-07-20 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.7bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.8bn | 2024-01-21 → 2024-07-20 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-43.05 | 2025-01-21 → 2025-07-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥120.66 | 2024-01-21 → 2025-01-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥155.36 | 2024-01-21 → 2024-07-20 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 45.7% | at 2025-07-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.6% | at 2025-01-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.1% | at 2024-07-20 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-01-21 → 2025-07-20 | −¥228m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-21 → 2025-07-20 | −¥228m |
| Reconciling Itemsreconciling | segment profit | 2025-01-21 → 2025-07-20 | −¥506m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥71.5bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥71.5bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥65m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | −¥2.0bn |
| jpcrp040300-q2r_E00424-000Dy Do Pharmareportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥263m |
| jpcrp040300-q2r_E00424-000Dy Do Pharmareportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥263m |
| jpcrp040300-q2r_E00424-000Dy Do Pharmareportable segment | segment profit | 2025-01-21 → 2025-07-20 | −¥184m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥10.4bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥10.4bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥3m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | ¥530m |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥28.8bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥28.8bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | ¥3.1bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥7.0bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥6.8bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥158m |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | ¥463m |
| —segment total | revenue | 2025-01-21 → 2025-07-20 | ¥117.9bn |
| —segment total | revenue external | 2025-01-21 → 2025-07-20 | ¥117.7bn |
| —segment total | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥228m |
| —segment total | segment profit | 2025-01-21 → 2025-07-20 | ¥1.9bn |
| Reconciling Itemsreconciling | revenue | 2024-01-21 → 2024-07-20 | −¥167m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-21 → 2024-07-20 | −¥167m |
| Reconciling Itemsreconciling | segment profit | 2024-01-21 → 2024-07-20 | −¥674m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue | 2024-01-21 → 2024-07-20 | ¥73.0bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue external | 2024-01-21 → 2024-07-20 | ¥73.0bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue intersegment | 2024-01-21 → 2024-07-20 | ¥17m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | segment profit | 2024-01-21 → 2024-07-20 | −¥238m |
| jpcrp040300-q2r_E00424-000Dy Do Pharmareportable segment | segment profit | 2024-01-21 → 2024-07-20 | −¥295m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue | 2024-01-21 → 2024-07-20 | ¥11.1bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue external | 2024-01-21 → 2024-07-20 | ¥11.1bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue intersegment | 2024-01-21 → 2024-07-20 | ¥3m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | segment profit | 2024-01-21 → 2024-07-20 | ¥899m |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue | 2024-01-21 → 2024-07-20 | ¥26.8bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue external | 2024-01-21 → 2024-07-20 | ¥26.8bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | segment profit | 2024-01-21 → 2024-07-20 | ¥2.3bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue | 2024-01-21 → 2024-07-20 | ¥6.9bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue external | 2024-01-21 → 2024-07-20 | ¥6.7bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue intersegment | 2024-01-21 → 2024-07-20 | ¥146m |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | segment profit | 2024-01-21 → 2024-07-20 | ¥324m |
| —segment total | revenue | 2024-01-21 → 2024-07-20 | ¥117.7bn |
| —segment total | revenue external | 2024-01-21 → 2024-07-20 | ¥117.6bn |
| —segment total | revenue intersegment | 2024-01-21 → 2024-07-20 | ¥167m |
| —segment total | segment profit | 2024-01-21 → 2024-07-20 | ¥3.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 550
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision for directors bonuses | CurrentQuarterInstant | 30000000 | JPY |
| Other cl | Prior1YearInstant | 7320000000 | JPY |
| Other cl | CurrentQuarterInstant | 6997000000 | JPY |
| Current liabilities | Prior1YearInstant | 63547000000 | JPY |
| Current liabilities | CurrentQuarterInstant | 67804000000 | JPY |
| Bonds payable | Prior1YearInstant | 10000000000 | JPY |
| Bonds payable | CurrentQuarterInstant | 15000000000 | JPY |
| Long term loans payable | Prior1YearInstant | 6963000000 | JPY |
| Long term loans payable | CurrentQuarterInstant | 11552000000 | JPY |
| Provision for directors retirement benefits | Prior1YearInstant | 18000000 | JPY |
| Provision for directors retirement benefits | CurrentQuarterInstant | 20000000 | JPY |
| Provision for share based remuneration for directors and other officers ncl | Prior1YearInstant | 247000000 | JPY |
| Provision for share based remuneration for directors and other officers ncl | CurrentQuarterInstant | 223000000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 2161000000 | JPY |
| Net defined benefit liability | CurrentQuarterInstant | 2197000000 | JPY |
| Other ncl | Prior1YearInstant | 8801000000 | JPY |
| Other ncl | CurrentQuarterInstant | 8749000000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 28192000000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 37743000000 | JPY |
| Liabilities | Prior1YearInstant | 91739000000 | JPY |
| Liabilities | CurrentQuarterInstant | 105548000000 | JPY |
| Capital stock | Prior1YearInstant | 1924000000 | JPY |
| Capital stock | CurrentQuarterInstant | 1924000000 | JPY |
| Capital surplus | Prior1YearInstant | 1868000000 | JPY |
| Capital surplus | CurrentQuarterInstant | 1862000000 | JPY |
| Retained earnings | Prior1YearInstant | 93036000000 | JPY |
| Retained earnings | CurrentQuarterInstant | 90879000000 | JPY |
| Treasury stock | Prior1YearInstant | -3520000000 | JPY |
| Treasury stock | CurrentQuarterInstant | -3411000000 | JPY |
| Shareholders equity | Prior1YearInstant | 93309000000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 91254000000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 1564000000 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | 2103000000 | JPY |
| Deferred gains or losses on hedges | Prior1YearInstant | 411000000 | JPY |
| Deferred gains or losses on hedges | CurrentQuarterInstant | 219000000 | JPY |
| Foreign currency translation adjustment | Prior1YearInstant | -4012000000 | JPY |
| Foreign currency translation adjustment | CurrentQuarterInstant | -4547000000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | 641000000 | JPY |
| Remeasurements of defined benefit plans | CurrentQuarterInstant | 583000000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | -1394000000 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | -1640000000 | JPY |
| Non controlling interests | Prior1YearInstant | 1592000000 | JPY |
| Non controlling interests | CurrentQuarterInstant | 1056000000 | JPY |
| Net assets | Prior1YearInstant | 93507000000 | JPY |
| Net assets | CurrentQuarterInstant | 90669000000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 185247000000 | JPY |
| Liabilities and net assets | CurrentQuarterInstant | 196218000000 | JPY |
| Net sales | Prior1YTDDuration | 117578000000 | JPY |
| Net sales | CurrentYTDDuration | 117701000000 | JPY |
| Cost of sales | Prior1YTDDuration | 63824000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |